Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer, Applied Biosystems, Cellzome, Wyeth, Ingenuity, Bruker AXS


PerkinElmer Reports Revenues, Income on Rise

PerkinElmer this week reported revenues of $432.6 million for the fourth quarter of 2003, up from $410 million for the same period in 2002.

The increase, which included a 6 percent boost from foreign currency exchange rate fluctuations, was driven by revenue growth in all segments, the company said in a statement.

The company had net income of $28 million for the quarter, compared to a loss of $2.6 million for the year-ago quarter. The company had net income of $52 million for the year, compared to a loss of $152 million for 2002.

PerkinElmer had research and development expenditures of $20 million for the fourth quarter, compared to $22 million for the year-ago period.

Cash and cash equivalents on hand at the end of the quarter totaled $191 million, compared to $131 million for the same period in 2002.

ABI reports increased revenue, strong MS

Applied Biosystems reported increased revenues and earnings for its fiscal year 2004 second quarter, along with slightly increased R&D spending.

For the period ending Dec. 31, 2003, ABI reported revenues of $458.4 million, compared to $444.7 million for the same period a year ago.

The company performed financially as expected, despite some deterioration in the business environment, Tony White, the chairman of Applera, ABI's parent company, said in a conference call.

In December, White said Applera had retained a strategic consultant to conduct an “in-depth review” of ABI's product portfolio. This week he said that the review, which the company today said will be completed this fiscal year, is not a cost-cutting exercise.

For Q2, revenues in mass spectrometry were $103.4 million, compared with $92.6 million in Q2 2003.

ABI’s net income for the quarter was $52.4 million, compared to $29.2 million in the prior year quarter. The company spent $60.7 million for R&D and engineering during the quarter, compared to $59.2 million the year before. ABI reported cash and cash equivalents of $640 million as of the end of the quarter.

White said the company's mass spectrometry business experienced “solid growth” and should continue to perform well serving growing markets in basic research and pharmaceutical development.

Michael Hunkapiller, president of ABI, said that revenue growth was impacted by the delay in the passage of the FY 2004 NIH budget, which consequently limited “some customers’ capital equipment purchases.”

Cellzome Publishes Complete Human Signaling Pathway In Nature Cell Bio

Cellzome this week published what it said was the first human signal transduction pathway to be mapped using a large-scale functional proteomics approach, in the February issue of Nature Cell Biology

The network, which was mapped using a combination of TAP tag-assisted purification of multi-protein complexes, LC-MS/MS, and RNAi techniques, illustrates an immune system signaling pathway triggered by cytokine tumor necrosis factor. It maps the interaction and formation of complexes. The methods that Cellzome used were first applied in 2002 to study yeast protein complexes, the company said in its paper.

Wyeth Licenses Ingenuity’s Network Analysis Application

Ingenuity of Mountain View, Calif. announced this week that Wyeth has licensed its Pathways Analysis system for drug discovery and development. The software uses a researcher’s gene or protein dataset and a database from Ingenuity to generate biological networks along with their associated functional analysis. Ingenuity has also licensed this application to SurroMed, the Genomics Institute of the Novartis Research Founcation, the Stanford Genome Technology Center, and GlaxoSmithKline.

Bruker AXS to Participate in Dutch Molecular Imaging Consortium, Will Receive €750,000

Bruker AXS expects to receive €750,000 ($953,000) over three years from the Dutch government to participate in a Dutch molecular imaging research consortium, the company said last week.

Bruker AXS, a subsidiary of Bruker BioSciences, will be part of the Cyttron consortium, a EUR17.6 million research project that is funded in half by the government of the Netherlands. The consortium aims to integrate data from X-ray crystallography, transmission electron microscopy, visible light microscopy, scanning microscopy, and NMR and make these techniques more compatible with each other.

Academic participants are joined by three companies; Delft-based Bruker AXS-subsidiary Bruker Nonius, FEI of Eindhoven, and KeyDP of Leiden.


The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.